Pfizer Pledges $100 Million to Fight Growing Threat of Antimicrobial Resistance
New Partnership with More than 20 Other Companies Will Focus on Medicines that Address Most Resistant Bacteria and Life-Threatening Infections
avatar
Staff or Guest writer for The Dog of Wall Street.
2020-07-09 20:02

Pfizer Inc. announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.

The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development.

While antibiotics revolutionized medicine in the 20th century and, together with vaccination, have led to the near eradication of many diseases in the developed world, over time, bacteria change and adapt to the use of antibiotics, rendering them ineffective. This makes it more difficult to treat common infections such as pneumonia, tuberculosis and salmonellosis, leading to longer hospital stays, higher medical costs and increased mortality.

“As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis”

Said Pfizer Chairman and Chief Executive Albert Bourla.

 


Disclaimer: I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2020-07-09 20:02

avatar
About the Author
Staff or Guest writer for The Dog of Wall Street.

PFE


Better Investment: Pfizer or Moderna
This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.
By Mike Sakuraba | 1 month ago

AstraZeneca confuses investors after reporting two different efficacy rates achieved by its Covid-19 vaccine
AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.
By Staff | 1 year ago

Pfizer Inc. initiates Covid-19 vaccine shipment trial
The company has selected Texas, New Mexico, Tennessee, and Rhode Island for the pilot program
By Staff | 1 year ago
PFE

Moderna Inc. (MRNA) says its Covid-19 vaccine more than 94 percent effective in Phase-III trials
Pfizer shares fell nearly 3 percent in the pre-market trading Monday following Moderna’s announcement.
By Staff | 1 year ago

Pfizer has a potential vaccine. Now what?
Industries like entertainment, travel and hospitality, airlines, cruise ships, and casinos, were just a few of the sectors that reacted positively to the news.
By Mike Sakuraba | 1 year ago
PFE

Pfizer Inc. (PFE) shares hit new 52-week high after positive results of Covid-19 vaccine
Pfizer says its experimental coronavirus vaccine more than 90 percent effective in trials
By Staff | 1 year ago